NO20062109L - Terapeutiske anvendelser av kjemokinvarianter - Google Patents

Terapeutiske anvendelser av kjemokinvarianter

Info

Publication number
NO20062109L
NO20062109L NO20062109A NO20062109A NO20062109L NO 20062109 L NO20062109 L NO 20062109L NO 20062109 A NO20062109 A NO 20062109A NO 20062109 A NO20062109 A NO 20062109A NO 20062109 L NO20062109 L NO 20062109L
Authority
NO
Norway
Prior art keywords
variants
therapeutic applications
chemokines
chemokine variants
inflammatory
Prior art date
Application number
NO20062109A
Other languages
English (en)
Inventor
Amanda Proudfoot
Jeffrey Shaw
Zoe Johnson
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20062109L publication Critical patent/NO20062109L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)

Abstract

Varianter av homodimerdarmende kjemokiner så som humant CCL2, med en enkel aminosyresubstitusjon i dimeriseringsgrensesnittet som endrer mønsteret av hydrogenbindinger og virker som en obligat monomer, kan antagonisere naturlige kjemokiner og har antiinflammatorisk aktivitet in vivo. Disse variantene kan brukes som aktive bestanddeler i farmasøytiske sammensetninger for behandling av inflammatoriske, autoimmune eUer infiserende sykdommer.
NO20062109A 2003-10-16 2006-05-11 Terapeutiske anvendelser av kjemokinvarianter NO20062109L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078308 2003-10-16
PCT/EP2004/052572 WO2005037305A1 (en) 2003-10-16 2004-10-18 Therapeutic uses of chemokine variants

Publications (1)

Publication Number Publication Date
NO20062109L true NO20062109L (no) 2006-05-11

Family

ID=34442986

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062109A NO20062109L (no) 2003-10-16 2006-05-11 Terapeutiske anvendelser av kjemokinvarianter

Country Status (16)

Country Link
US (1) US7740833B2 (no)
EP (1) EP1673103A1 (no)
JP (1) JP2007510403A (no)
KR (1) KR20070008510A (no)
CN (1) CN1867352A (no)
AR (1) AR046594A1 (no)
AU (1) AU2004281552B2 (no)
BR (1) BRPI0415290A (no)
CA (1) CA2536082A1 (no)
EA (1) EA009414B1 (no)
IL (1) IL175020A0 (no)
MX (1) MXPA06003695A (no)
NO (1) NO20062109L (no)
UA (1) UA91820C2 (no)
WO (1) WO2005037305A1 (no)
ZA (1) ZA200601900B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002101A (es) * 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
WO2007148317A1 (en) * 2006-06-21 2007-12-27 Compugen Ltd. Mcp-1 splice variants and methods of using same
JP2009544690A (ja) * 2006-07-24 2009-12-17 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｃｃｌ２を含む医薬組成物および炎症の処置のためのその使用
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
BRPI1008167A2 (pt) * 2009-01-30 2016-03-29 Protaffin Biotechnologie Ag mutantes de mcp-1 antagonizando glicosaminoglicano e método de usar os mesmos
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US20130330337A1 (en) * 2011-06-01 2013-12-12 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US9249204B2 (en) 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US8541564B2 (en) * 2011-06-01 2013-09-24 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
EP2718311B1 (en) * 2011-06-13 2018-01-17 TLA Targeted Immunotherapies AB Treating multiple sclerosis
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
CN107207603A (zh) * 2015-02-03 2017-09-26 吉安特科技股份有限公司 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR102066149B1 (ko) * 2018-08-17 2020-01-14 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 임신촉진용 조성물
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507211A (ja) * 1993-09-14 1997-07-22 ナショナル ハート アンド ラング インスティチュート エオタキシン：好酸球走化性サイトカイン
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
JP3837748B2 (ja) * 1997-01-17 2006-10-25 東亞合成株式会社 Ｖｅｇｆ結合性ポリペプチド
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
JP4793971B2 (ja) * 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
ATE384783T1 (de) * 2001-10-19 2008-02-15 Zymogenetics Inc Dimerisierter wachstumsfaktor sowie materialien und verfahren zu seiner herstellung
WO2003083059A2 (en) * 2002-03-26 2003-10-09 Centocor, Inc. Mcp-1 mutant proteins, antibodies, compositions, methods and uses
EP1495050A1 (en) 2002-04-10 2005-01-12 Applied Research Systems ARS Holding N.V. Novel antagonists of mcp proteins
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors

Also Published As

Publication number Publication date
BRPI0415290A (pt) 2006-12-19
US7740833B2 (en) 2010-06-22
US20070280958A1 (en) 2007-12-06
AR046594A1 (es) 2005-12-14
AU2004281552A1 (en) 2005-04-28
UA91820C2 (ru) 2010-09-10
EA009414B1 (ru) 2007-12-28
MXPA06003695A (es) 2006-06-20
CA2536082A1 (en) 2005-04-28
ZA200601900B (en) 2007-07-25
JP2007510403A (ja) 2007-04-26
AU2004281552B2 (en) 2009-10-22
CN1867352A (zh) 2006-11-22
EP1673103A1 (en) 2006-06-28
WO2005037305A1 (en) 2005-04-28
KR20070008510A (ko) 2007-01-17
IL175020A0 (en) 2006-08-20
EA200600782A1 (ru) 2006-08-25

Similar Documents

Publication Publication Date Title
NO20062109L (no) Terapeutiske anvendelser av kjemokinvarianter
HUP0301246A2 (hu) Humán véralvadási faktor VII változatai
ATE437663T1 (de) Legierungszusammensetzungen und diese enthaltende vorrichtungen
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
SG162788A1 (en) Self-buffering protein formulations
ATE554722T1 (de) System zur bereitstellung zahnärztlicher vorrichtungen in einer sequenz
WO2006081573A3 (en) Homogeneous preparations of il-31
CY1111703T1 (el) Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους
HUP0401124A2 (hu) VII koagulációs faktor származékok
MX2010003574A (es) Anticuerpos il-23.
NO20061291L (no) Ny formulering
CR20220249A (es) Derivados terapéuticos de interleucina-22
ATE422201T1 (de) 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
WO2007134118A3 (en) Protein based composition and methods of using same
DE60108076D1 (de) Protein c derivate
BR112012000410B8 (pt) uso de benzidamina ou dos sais de adição de ácido, e, composição farmacêutica
IL169256A (en) Polypeptide having metalloprotease activity, nucleic acid encoding it and pharmaceutical composition comprising it
ATE501728T1 (de) Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях
ATE343633T1 (de) Allele formen von menschlichem stat3
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application